In addition, recent randomized clinical trials of JAK inhibitors for RA demonstrated equivalent or even superior efficacy to adalimumab, a tumor necrosis factor (TNF) inhibitor [7–10]. The gene discussed is TNF; the disease is rheumatoid arthritis.